Benzinga | Oct 2, 2020 08:33AM EDT

Tenax Therapeutics To Present Clinical Trial Presentation Of Phase 2 HELP Study At Heart Failure Society Of America (HFSA) Virtual Annual Scientific Meeting Oct. 3

* HELP Study results will be presented on Saturday, October 3, 2020 at 4:30 pm EDT

Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF will be presented at the upcoming Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting to be held September 30, - October 6. Scheduling details and registration information are provided below:

Levosimendan Improves Hemodynamics and Submaximal Exercise CapacityTitle: In PH-HFpEF: Primary Results From The HELP-PH-HFpEF Multicenter Randomized Controlled Trial



Speaker: Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic



Session: Late-Breaking Clinical Trials I (LBCT I)



Date/ Saturday, October 3, 4:30 - 5:30 PMTime: